Dual-target car-t cell therapy for multiple myeloma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of immunotherapy using your own immune cells (called CAR-T cells) that are modified to attack two targets (CD19 and BCMA) on myeloma cells. It is for patients whose myeloma has come back or stopped responding to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your myeloma has not responded to or has worsened after at least 3 cycles of standard treatments like bortezomib or lenalidomide.
- Cancer cells in your bone marrow or a tumor sample must show high levels (30% or more) of a protein called BCMA.
- You must be well enough to undergo apheresis (a procedure to collect your white blood cells) and have adequate kidney, liver, and blood cell counts.
- You have not had certain prior cell therapies (like CAR-T) or strong chemotherapy within specific timeframes.
- You do not have active serious infections, uncontrolled heart problems, or other major health conditions that would make the trial unsafe.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
This trial tests a new CAR-T cell treatment that targets two proteins (BCMA and CD19) on myeloma cells. It is for patients whose multiple myeloma has come back or stopped responding to other treatments and has spread to tissues outside the bone marrow.
This early trial tests a new CAR-T cell treatment targeting three proteins (CD19, CD22, and BCMA) on myeloma cells. It's for people whose myeloma came back or didn't respond to at least three prior treatments.
This trial tests a new CAR-T cell treatment that targets two proteins (BCMA and GPRC5D) on myeloma cells. It is for patients whose multiple myeloma has come back or stopped responding to treatment and has spread outside the bone marrow (extramedullary disease). The goal is to see if this dual-target approach can attack the cancer more effectively.
This trial tests a one-time BCMA CAR-T cell treatment for people with multiple myeloma that relapsed or did not respond well to prior treatments. It may help by training your own immune cells to recognize and attack myeloma cells.
This trial tests a new CAR-T cell therapy that targets two proteins (BCMA and CD19) on myeloma cells. It may help patients whose myeloma has come back or stopped responding to previous treatments.
Hear when a new Relapse Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.